Cost-effectiveness of initiating extrafine- or standard size-particle inhaled corticosteroid for asthma in two health-care systems: a retrospective matched cohort study.

ABSTRACT:

Background

Real-life studies are needed to determine the cost-effectiveness of asthma therapies in clinical practice.

Aim

To compare the cost-effectiveness of extrafine-particle inhaled corticosteroid (ICS) with standard size-particle ICS in the United Kingdom (UK) and United States (US).

Methods

These retrospective matched cohort analyses used large electronic databases to study asthma-related outcomes for patients in the UK (12-60 years old; n=1730) and US (12-80 years; n=10,312) prescribed extrafine beclomethasone or fluticasone as their first ICS therapy for asthma. Patients were matched on demographic characteristics and asthma severity during 1 baseline year, and asthma control and asthma-related costs were compared during 1 outcome year.

Results

In both

SUBMITTER: Martin RJ 

PROVIDER: S-EPMC4373495 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature